The company is focused on mammalian expression systems for the production of viral vectors and recombinant proteins. HALIX leverages scalable single-use, state-of-the-art bioprocessing technologies to supply its customers with the development and GMP manufacturing of drug substance (API) and drug product. As an end-to-end service provider, HALIX supports its customers all the way from clinical dev
elopment up to commercial launch and product registration. HALIX has entered a number of cooperations for production of immunotherapeutic monoclonal and bispecific antibodies utilizing innovative technologies. Within the last years, HALIX successfully produced viral vectors to treat cancer and vaccinations to prevent infectious diseases, such as COVID-19, HIV, ZIKA, Chikungunya and Influenza. Building on the successes with its customers and partners, HALIX is expanding its capacities to meet both current and future supply chain needs. HALIX recently opened its state-of-the-art 6,700 m2 GMP manufacturing facility at the Bio Science Park in Leiden, the Netherlands. The facility design supports clinical and commercial production in BSL2 cleanrooms with a capacity up to 1,000L single-use bioreactor capacity. Laboratory spaces offer comprehensive and qualifies process development, analytical development and quality control services.
